



### MICROMEDEX EDITORIAL EXCELLENCE

# Trusted insights grounded in proven clinical review practices

For confident decisions backed by transparency and clearly presented evidence

Four reasons why Micromedex continues to be trusted by clinicians around the world:

#### Transparency

Our editorial process ensures a clear and meticulous presentation of evidence. We make it easy to see where each piece of information originates, empowering your decision-making with complete confidence.

#### **Context matters**

No two patients are the same, and clinicians at every level require tools and insights tailored to their unique situations and the patients they serve. Whether supporting students or specialists, we provide critical context that helps apply evidence effectively, enabling informed care for patients at every stage of life. Pediatric content is based on population-specific evidence rather than simply extrapolating from adult data, ensuring superior accuracy and relevancy.

#### **Expert-driven insights**

At the core of Micromedex is a diverse team of drug information experts, board-certified clinical pharmacists, toxicologists, nurses, medical writers, and data scientists. With expertise in literature evaluation and specialty clinical practice, this team delivers carefully analyzed and evidence-based insights across specialties, patient populations, and disease states.

#### Unbiased methodology

Every decision to include or exclude evidence is guided by an objective, rigorous process. Free from external influences or affiliations, our approach guarantees neutrality and integrity. "As far as my go-to source for pediatrics and neonatal, Micromedex is my number one. That's what I rely on and that is what the neonatologists rely on."


Anthony Bono Pharmacist Englewood Hospital

## Transparency


Whether making a quick validation or researching complex cases in vulnerable patients, the transparent and clear presentation of evidence in Micromedex supports informed, confident clinical decision-making and helps clinicians enhance patient safety and improve clinical outcomes.

Making informed decisions requires access to all relevant information, including potential outcomes, benefits and risks. Micromedex provides a clear picture of the best available evidence, including meaningful summaries of the literature and guidelines, and clear evidence ratings.

All evidence is not equal. Even when only expert opinion or lower levels of evidence are available, Micromedex ensures clinicians have the critical context to apply that evidence appropriately. Recommendation and evidence ratings will, where appropriate, indicate where a given treatment is not useful or should be avoided.



Transparent, actionable, and clearly presented insights



Unbiased information grounded in the best available evidence

Fully cited for integrity, easy reference, and access to further detail

Non-FDA Uses		
Administration		
	Cancer - Venous thromboembolism	
Comparative Efficacy Place In Therapy	1) Overview FDA Approval: Adult, no; Pediatric, no	
Medication Safety	Efficacy: Adult, Effective	
Contraindications	Recommendation: Adult, Class IIa	
Precautions	Strength of Evidence: Adult, Category B	References ×
Adverse Effects	See Drug Consult reference: RECOMMENDATION AND EVIDENCE RATINGS	
Boxed Warning	2) Summary:	[8] Key NS, Khorana AA, Kuderer NM, et al: Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Guideline Update. J Clin Oncol 2023; Epub:Epub. PubMed Abstract: http://www.ncbi.nlm.nih.gov/
REMS	Evidence • The incidence of recurrent VTE with apixaban was noninferior to that with dalteparin in the randomized CARAVAGGIO trial [6] and was significantly reduced with apixaban compared with dalteparin in the randomized ADAM VTE trial [7], both of which enrolled adults with active cancer and acute VTE [6][7]. There were no significant differences in the incidences of major bleeding [6][7], clinically relevant non-major bleeding [6], and major plus clinically relevant non-	
Drug Interactions (single)		
IV Compatibility (single)		
Pregnancy & Lactation		
Monitoring	major bleeding [7].	Close
Do Not Confuse	Guidelines (American Society of Clinical Oncology [ASCO])	Close
Mechanism of Action	<ul> <li>Initiate anticoagulation with low molecular weight heparin (LMWH), unfractionated heparin, fondaparinux, rivaroxaban, or apixaban for treatment of patients with cancer and established VTE to prevent recurrence (strong recommendation based on high-quality evidence) [8].</li> <li>Long-term anticoagulation for at least 6 months should include LMWH, edoxaban, rivaroxaban, or apixaban instead of a</li> </ul>	
Mechanism of Action		
Pharmacokinetics	vitamin K antagonist (VKA) for improved efficacy; a VKA may be used if LMWH or direct factor Xa inhibitors are not accessible. Use caution with direct factor Xa inhibitors in castrointestinal and rentrumnary malionancies or other	

 $(\mathcal{O})$ 

Fully cited content, with in-line referencing for transparency and easy access to further detail

## Context matters

When treating the patient in front of you, context can make all the difference to patient safety and positive clinical outcomes. No two patients are the same, and different care team stakeholders require different levels of content and tools at different times. Micromedex provides fast answers based on the world's best available evidence that the whole care team can trust, all in one place. It's what healthcare professionals around the world, across the spectrum of students to specialists, rely on when caring for their very youngest to the oldest of patients.

Providing safe and effective drug therapies for the most vulnerable populations, such as neonates, infants and children, requires consideration of clinically significant differences. Micromedex NeoFax® and Pediatrics provides population-specific information for dosage, administration, pharmacokinetics, monitoring and potential side effects which can be different and clinically relevant across these populations. When time is critical in managing toxic exposures or overdoses, this resource delivers fast, concise answers to guide identification and treatment. A comprehensive tool for toxicologists, it covers patient triage, clinical effects, range of toxicity, product information, and treatment recommendations. Information spans active ingredients, excipients, pH level, physical description and slang terms, providing evidence-based insights on commercial products, chemicals, drugs of abuse, toxic plants, and animals.

Clear patient understanding of health conditions and self-care is key to better outcomes. Micromedex patient education and engagement materials are visual, simple, and written in plain language to support health literacy standards. Available in 15 languages and expanding, they ensure accessibility for diverse audiences.

How is asthma in children diagnosed? Tell your child's pediatrician if your child has a family history of asthma. Tell the provider about your child's symptoms and what you think may trigger symptoms. The provider will examine your child and listen to his or her lungs. Your child may need to be tested for allergies that could trigger asthma attacks. He or she may also need the following:

Pulmonary function tests (PFTs) are done to show how well your child can breathe.



A chest x-ray is used to check for other lung problems such as an infection.

Patient education materials are visual, simple and written in plain language - in multiple languages

#### When all patients are not the same



Comparative efficacy insights to support alternative therapy decisions



Population-specific evidence tailored to age and indication

Context and evidence ratings

to support off-label use



Multilingual, easy-tounderstand patient education

# Б

Place in therapy guidance on a drug's role in overall treatment



Quick answers for managing toxicological exposures

# Apixaban Cancer - Venous thromboembo FDA Approval: Adult, no Pediatric, no Efficacy: Adult. Effective Strength of Recommendat Adult, Class IIa Strength of Evidence: Adult, Category B Close

Evidence ratings for transparent risk:benefit consideration

## Expert-driven insights

A team of in-house experts sits behind every answer in Micromedex. This team includes board-certified clinical pharmacists and toxicologists, nurses, medical writers, and data scientists. It also includes those with advanced training and clinical experience in key specialty areas such as pediatrics, psychiatry, critical care, drug information, infectious diseases, and oncology. To ensure the highest level of accuracy and reliability, the editorial process is further enriched through collaboration with a distinguished network of external expert consultants.

Skilled in research methodologies and with expertise in literature evaluation and clinical practice, this team critically evaluates evidence to deliver insights across specialties, patient populations, and disease states. A number of the team members continue to actively practice, contributing current insights to better meet the changing needs of clinicians.

We understand that user needs and clinical evidence evolve. which is why we value client feedback and work collaboratively to adapt and meet those needs effectively.

"The National Institute for Health and Care Excellence (NICE) accredited the Micromedex content development process as a mark of quality between 2013 and 2024 before closing its accreditation programme in August 2024."

Mark Minchin Associate Director – Quality National Institute for Health and Care Excellence (NICE)

# Unbiased methodology


The Micromedex editorial process is a safe pair of hands. The objectivity around which its content is created has led to accreditation from NICE, the National Institute for Health and Care Excellence, for our content development process. In addition, Micromedex is approved for use by CMS (Centers for Medicare and Medicaid Services) in its program for compendia use in the determination of medically accepted indications of drugs and biologicals used beyond package labeling in an anticancer chemotherapeutic regimen.

Surveillance of global medical literature ensures a comprehensive review of the full body of evidence, supporting fully informed recommendations. This includes automated monitoring of published research, regulatory alerts, clinical guidelines, and professional notices, combined with targeted searches by medical librarians for new topics and focused updates.

Critical evaluation filters out the noise of flawed information to highlight the strongest evidence available. This process involves analyzing study design, participant data, statistical methods, conclusions against predefined objectives, and measures of internal validity.

Prioritization is based on safety impact, clinical importance, application of product usage data and potential to change practice.

Content development is a multi-step, iterative process amongst editors with clinical expertise followed by peer review.



The rigorous and unbiased content development process

## A resource you can continue to trust

For over 50 years, clinicians across 80+ countries have trusted Micromedex for accurate, high-quality information to support patient care decisions. Backed by decades of experience, we're focused on meeting the future needs of our users. As technology evolves, so do we – thoughtfully leveraging innovative technologies alongside our expertise to deliver exceptional content and ever-improving user experience for our customers.

Studies can find statistical significance, AI can search vast bodies of evidence – but only humans can establish clinical relevance. Our goal is to accelerate your clinical workflow with fast, tailored, and clinically validated responses, built on the trusted evidence and transparent references of Micromedex – without compromising on reliability, precision and depth.

# Learn more about our solutions

merative.com/clinical-decision-support

## About Micromedex

Micromedex by Merative is trusted by healthcare professionals in over 80 countries to provide award-winning clinical decision support solutions for drug and disease information and patient education. Micromedex was named Best in KLAS 2023 (clinical decision support: point of care clinical reference), is recognized as a CMS compendium, and has been recognized for its robust editorial process.

Learn more at merative.com/micromedex

## About Merative

Merative provides data, analytics, and technology for healthcare and government social services. With focused innovation and deep expertise, Merative works with providers, employers, health plans, governments, and life sciences companies to improve decisionmaking and performance. © Merative US L.P. 2025. All Rights Reserved.

Produced in the United States of America April 2025

Merative and the Merative logo are trademarks of Merative US L.P. Other product and service names might be trademarks of Merative or other companies.

The information contained in this publication is provided for informational purposes only. While efforts were made to verify the completeness and accuracy of the information contained in this publication, it is provided AS IS without warranty of any kind, express or implied. In addition, this information is based on Merative's product plans and strategy as of the date of this publication, which are subject to change by Merative without notice. Nothing contained in this publication is intended to, nor shall have the effect of, creating any warranties or representations from Merative, or stating or implying that any activities undertaken by you will result in any specific performance results. Merative products are warranted according to the terms and conditions of the agreements under which they are provided.

MDX-9151348818 Rev 1.0

